Alk-Abello ASCHIX:ALKBC 92 5-Year Yield-on-Cost % is 0.62 as of Jul. 11, 2026, which is 15% above its 10-year median of 0.54. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr207.94 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, Alk-Abello AS ranks worse than 76.47% on this metric.
Alk-Abello AS's yield on cost for the quarter that ended in Mar. 2026 was 0.62.
The historical rank and industry rank for Alk-Abello AS's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:ALKBc'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.43 Med: 0.54 Max: 0.78
Current: 0.62
During the past 13 years, Alk-Abello AS's highest Yield on Cost was 0.78. The lowest was 0.43. And the median was 0.54.
CHIX:ALKBc's 5-Year Yield-on-Cost % is ranked worse than 76.47% of 153
companies
in the Biotechnology industry
Industry Median: 1.65
vs CHIX:ALKBc: 0.62
Alk-Abello AS (CHIX:ALKBc) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alk-Abello AS 5-Year Yield-on-Cost % Related Terms
CHIX:ALKBC vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Alk-Abello AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Alk-Abello AS is calculated as
Alk-Abello AS (CHIX:ALKBC) has a 5-Year Yield-on-Cost % of 0.62 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alk-Abello AS and its competitors. This is 15% above median its historical median of 0.54. Over the past decade, Alk-Abello AS's 5-Year Yield-on-Cost % has ranged from 0.43 to 0.78. According to the industry distribution chart, Alk-Abello AS ranks #117 out of 153 companies in the Biotechnology industry, placing it in the top 76.5%.
Is Alk-Abello AS's 5-Year Yield-on-Cost % too high?
Alk-Abello AS's current 5-Year Yield-on-Cost % of 0.62 is 15% above median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.78. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.65. Alk-Abello AS's value of 0.62 is 62.4% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #117 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #117 out of 153 companies for 5-Year Yield-on-Cost %. This places Alk-Abello AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.65. Alk-Abello AS's value of 0.62 is 62.4% below this benchmark. Historically, Alk-Abello AS's own 5-Year Yield-on-Cost % has ranged from 0.43 to 0.78 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 1.65, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current 5-Year Yield-on-Cost % of 0.62 is 62.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current 5-Year Yield-on-Cost % is 0.62, which is 15% above median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.94, compared to a current price of kr256.30 — trading 23.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.62, which is 15% above median its 10-year median of 0.54 and 62.4% below the Biotechnology industry median of 1.65. Alk-Abello AS's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current 5-Year Yield-on-Cost % is 0.62 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.3% above its estimated GF Value™ of kr207.94.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
5-Year Yield-on-Cost %: 0.62 (15% above median its 10-year median of 0.54)
GF Value™: kr207.94 vs. price of kr256.30 (23.3% above fair value)
Industry Position: 62.4% below the Biotechnology median (#117 of 153)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 